Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trandolapril

FDA-approved product (tablet, oral), marketed as Mavik, Trandolapril.

Registered studies
29
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Trandolapril
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Ventricular Dysfunction, Left

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
FDA pharmacologic class
Angiotensin Converting Enzyme Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

29registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trandolapril in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trandolapril with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

    NCT07547878 · start 2026-04-30

    Registered record
    Registry ID
    NCT07547878
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes
    Interventions
    Finerenone; Semaglutide; Lotensin; Capoten; Enalapril; Monopril; Lisinopril; Univasc; Aceon; Accupril; Altace; Mavik; Edarbi; Atacand; Avapro; Cozaar; Benicar; Micardis; Diovan; Invokana; Farxiga; Jardiance; Ertugliflozin; Brenzavvy; Sotagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04-30
    Completion
    2029-03-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes
    InterventionFinerenone; Semaglutide; Lotensin; Capoten +21 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.

    NCT07513883 · start 2026-03-16

    Registered record
    Registry ID
    NCT07513883
    Conditions
    Heart Failure
    Interventions
    Down-titration; Continuation of guideline-directed heart failure therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-16
    Completion
    2028-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionDown-titration; Continuation of guideline-directed heart failure therapy
    PhasePhase 4
    Registry statusRecruiting

  • Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

    NCT07262710 · start 2025-12-01

    Registered record
    Registry ID
    NCT07262710
    Conditions
    Post-stroke Pneumonia
    Interventions
    angiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2026-08-19
    Enrolment
    13,656

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-stroke Pneumonia
    Interventionangiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

    NCT05498675 · start 2021-09-01

    Registered record
    Registry ID
    NCT05498675
    Conditions
    Sacubitril/Valsartan; Hypertension; Obesity
    Interventions
    Sacubitril / Valsartan Oral Tablet [Entresto]; ACEI/ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-09-01
    Completion
    2027-06-30
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSacubitril/Valsartan; Hypertension; Obesity
    InterventionSacubitril / Valsartan Oral Tablet [Entresto]; ACEI/ARB
    PhaseNot recorded
    Registry statusRecruiting

  • Coronavirus (COVID-19) ACEi/ARB Investigation

    NCT04330300 · start 2020-04-30

    Registered record
    Registry ID
    NCT04330300
    Conditions
    Hypertension; COVID-19
    Interventions
    Thiazide or Thiazide-like diuretics; Calcium Channel Blockers; ACE inhibitor; Angiotensin receptor blocker
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2020-04-30
    Completion
    2021-12-01
    Enrolment
    2,414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID-19
    InterventionThiazide or Thiazide-like diuretics; Calcium Channel Blockers; ACE inhibitor; Angiotensin receptor blocker
    PhasePhase 4
    Registry statusSuspended

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

    NCT02735707 · start 2016-04-11

    Registered record
    Registry ID
    NCT02735707
    Conditions
    Community-acquired Pneumonia, Influenza, COVID-19
    Interventions
    Ceftriaxone; Moxifloxacin or Levofloxacin; Piperacillin-tazobactam; Ceftaroline; Amoxicillin-clavulanate; Standard course macrolide; Extended course macrolide; No systemic corticosteroid; Fixed-duration Hydrocortisone; Shock-dependent hydrocortisone; Fixed-duration higher dose Hydrocortisone; No antiviral agent for influenza; Five-days oseltamivir; Ten-days oseltamivir; No antiviral agent for COVID-19; Lopinavir / Ritonavir; Hydroxychloroquine; Hydroxychloroquine + lopinavir/ritonavir; Ivermectin; No immune modulation for COVID-19; Interferon beta-1a; Anakinra; Tocilizumab; Sarilumab; Local standard venous thromboprophylaxis; Therapeutic dose anticoagulation; Conventional low dose thromboprophylaxis; Intermediate dose thromboprophylaxis; Continuation of therapeutic dose anticoagulation; No immunoglobulin; Convalescent plasma; Delayed administration of convalescent plasma; No vitamin C; Vitamin C; No antiplatelet; Aspirin; P2Y12 inhibitor; No simvastatin; Simvastatin; Eritoran; Apremila
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2016-04-11
    Completion
    2028-02
    Enrolment
    20,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-acquired Pneumonia, Influenza, COVID-19
    InterventionCeftriaxone; Moxifloxacin or Levofloxacin; Piperacillin-tazobactam; Ceftaroline +37 more
    PhasePhase 3
    Registry statusRecruiting

  • NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

    NCT02817360 · start 2016-02

    Registered record
    Registry ID
    NCT02817360
    Conditions
    Heart Diseases; Diabetes Mellitus, Type 2
    Interventions
    RAS-antagonist and beta-blocker up-to maximal dosages; RAS-antagonist and beta-blocker none or at stable dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2016-02
    Completion
    2026-12
    Enrolment
    2,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Diseases; Diabetes Mellitus, Type 2
    InterventionRAS-antagonist and beta-blocker up-to maximal dosages; RAS-antagonist and beta-blocker none or at stable dose
    PhasePhase 4
    Registry statusRecruiting

  • Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

    NCT01669434 · start 2015-06-01

    Registered record
    Registry ID
    NCT01669434
    Conditions
    Hypotension on Induction
    Interventions
    ACEI continuation; ACEI omission
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06-01
    Completion
    2016-12-01
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypotension on Induction
    InterventionACEI continuation; ACEI omission
    PhasePhase 4
    Registry statusCompleted

  • ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

    NCT01867047 · start 2013-06

    Registered record
    Registry ID
    NCT01867047
    Conditions
    Adverse Effects of Angiotensin-converting-enzyme Inhibitors; Hypotension
    Interventions
    ACE-I Cessation group; ACE-I Continuation group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2016-06-24
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Effects of Angiotensin-converting-enzyme Inhibitors; Hypotension
    InterventionACE-I Cessation group; ACE-I Continuation group
    PhaseNot applicable
    Registry statusTerminated

  • Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics

    NCT01715584 · start 2012-07

    Registered record
    Registry ID
    NCT01715584
    Conditions
    Hypertension
    Interventions
    Sevoflurane/oxygen/air/nitrous oxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-07
    Completion
    2019-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionSevoflurane/oxygen/air/nitrous oxide
    PhasePhase 4
    Registry statusUnknown

  • Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?

    NCT01437371 · start 2011-08

    Registered record
    Registry ID
    NCT01437371
    Conditions
    Heart Failure
    Interventions
    - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2014-06
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    Intervention- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension

    NCT01127139 · start 2010-04

    Registered record
    Registry ID
    NCT01127139
    Conditions
    Essential Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-04
    Completion
    2011-03
    Enrolment
    3,828

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients

    NCT01078584 · start 2008-12

    Registered record
    Registry ID
    NCT01078584
    Conditions
    Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-12
    Completion
    2011-09
    Enrolment
    7,993

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)

    NCT00887510 · start 2007-05

    Registered record
    Registry ID
    NCT00887510
    Conditions
    Hypertension
    Interventions
    Hydrochlorothiazide; Trandolapril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-05
    Completion
    2009-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionHydrochlorothiazide; Trandolapril
    PhasePhase 4
    Registry statusCompleted